Parnell Pharmaceuticals Holdings Debt to Equity Ratio 2014-2018 | PARNF
Current and historical debt to equity ratio values for Parnell Pharmaceuticals Holdings (PARNF) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Parnell Pharmaceuticals Holdings debt/equity for the three months ending June 30, 2018 was 0.00.
| Parnell Pharmaceuticals Holdings Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2018-06-30 |
$0.03B |
$-0.01B |
-3.31 |
| 2018-03-31 |
$0.03B |
$-0.01B |
-3.23 |
| 2017-12-31 |
$0.03B |
$-0.01B |
-3.67 |
| 2016-12-31 |
$0.03B |
$0.01B |
4.91 |
| 2016-09-30 |
$0.02B |
$0.01B |
2.21 |
| 2015-12-31 |
$0.02B |
$0.02B |
1.28 |
| 2015-09-30 |
$0.00B |
|
0.00 |
| 2015-06-30 |
$0.02B |
$0.02B |
0.72 |
| 2015-03-31 |
$0.00B |
|
0.00 |
| 2014-12-31 |
$0.01B |
$0.03B |
0.42 |
| 2014-09-30 |
$0.00B |
|
0.00 |
| 2014-06-30 |
$0.01B |
$0.03B |
0.30 |
| 2014-03-31 |
$0.03B |
$0.00B |
-16.70 |
| 2013-06-30 |
$0.03B |
$0.00B |
12.23 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.000B |
$0.000B |
|
Parnell Pharmaceuticals Holdings Ltd. is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing animal health solutions. It manufactures and markets cattle reproduction, cattle mastitis, anesthetics, laminitis treatment, and orthopedic treatment products. The Company operates in four segments: Companion Animal, Production Animal-Unites States, and Production Animal-rest of the world and Manufacturing Operations. ZYDAX (R), GLYDE (R) and TERGIVE (R) are Parnell's premium osteoarthritis product suite. Parnell Pharmaceuticals Holdings Ltd. is headquartered in Alexandria, Australia.
|
